Tilak Healthcare

What Tilak Healthcare does

Tilak Healthcare is a Paris-based digital therapeutics company founded in 2016 by Edouard Gasser (ex-Gameloft) and Pr José-Alain Sahel (founder of the Vision Institute in France). Its core product, OdySight®, is a CE-marked mobile medical application prescribed by ophthalmologists for remote monitoring of chronic maculopathies, primarily age-related macular degeneration (AMD/DMLA). The platform combines clinically validated vision tests (visual acuity and Amsler grid) with a gamification layer (puzzle-based "tetro-cross" mechanics using energy points) specifically designed to maintain adherence among senior and low-vision patients—an engagement problem that has driven 77% three-day churn on comparable apps. Patented computer-vision algorithms handle eye-to-screen distance calculation and ambient light detection to ensure clinical-grade test accuracy, and machine learning–based anomaly detection triggers alerts when visual acuity scores fall below acceptable thresholds, with notifications sent to both patient and physician through a dedicated monitoring dashboard.

The company operates a hybrid revenue model with two primary streams: (1) healthcare reimbursement under France's national system via the PECAN scheme (positive HAS opinion October 2025) and Article 51 experimentation (initiated 2022), and (2) licensing/co-promotion agreements with major pharmaceutical partners including Novartis France (since 2019) and Laboratoires Théa (since 2022). Distribution is multimodal—ophthalmologist prescription, mobile app stores (iOS/Android), pharmaceutical partner networks, and direct physician dashboards—with the company serving patients in France (primary), Spain (deployed 2022 via Novartis), and targeting Belgium, Germany, and the United States. Customer-base scale reached 30,000+ patients and 1,200+ physicians by October 2025, up from 12,000 patients in October 2023.

Tilak has raised approximately €22 million across three funding rounds (March 2017 €2.5M seed from iBionext; October 2021 €7M Series A led by Elaia; October 2023 €10M round co-led by Elaia and CapHorn with participation from Laboratoires Théa, Matmut, and Swen). The company holds ISO 13485:2016 certification (assessed by BSI), received the Prix Galien 2020 in the e-health category, and won the Innov'up Leader PIA award (€348K) in 2025. Management has signaled an ambition to reach profitability in 2025, coinciding with the PECAN reimbursement approval. The firm is also developing TLK-002, a second medical game targeting opioid dependency, representing an early diversification beyond ophthalmology.

Name

Tilak Healthcare

Legal name

Tilak Healthcare SAS

Website

https://tilakhealthcare.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Tilak Healthcare is a Paris-based digital therapeutics company developing OdySight®, a CE-marked mobile application that combines clinically validated vision tests with gamification for remote monitoring of chronic macular diseases, prescribed by ophthalmologists and reimbursed under France's PECAN scheme.

Ownership category

akta.pro rank

Product category

Digital Health / Digital Therapeutics (Ophthalmology)

NAICS

Home Health Care Services (62161)

SIC

Surgical & Medical Instruments & Apparatus (3841), Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK)

akta.pro secondary industries

Edge-Based Clinical Decision Support & Alerts (On-Device/On-Prem Analytics) (HLACAPAL), Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity) (HLAHAJAC)

Keywords

• Digital therapeutics
• Ophthalmology monitoring
• Medical mobile apps
• Vision testing software
• Chronic disease management

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Others

Revenue model

1. Healthcare Reimbursement / Subscription: Tilak Healthcare generates revenue through national health system reimbursement in France via the PECAN program and Article 51 experimentation scheme. The OdySight® application is prescribed by ophthalmologists and reimbursed as a digital medical device for chronic maculopathy monitoring.
2. Pharmaceutical Partnership Licensing: Revenue generated through co-promotion partnerships with pharmaceutical companies (Novartis France, Théa) for distribution and promotion of OdySight® to patients with chronic eye diseases. Partnerships provide market access and revenue sharing arrangements.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Tilak Healthcare develops OdySight®, a CE-marked medical mobile application prescribed by ophthalmologists for the remote monitoring of chronic maculopathies (such as age-related macular degeneration). The platform combines clinically validated vision tests (visual acuity and Amsler grid) with a gamified puzzle experience designed to drive sustained patient engagement, transmitting test results and abnormal-result alerts to physicians via a dedicated dashboard.

Product overview

Tilak Healthcare operates as a digital health platform focused on ophthalmology, built around its core product OdySight®, a CE-marked medical mobile application. The platform combines clinically validated vision tests (visual acuity, Amsler grid) with gamification mechanics to monitor chronic maculopathies remotely. The ecosystem includes a physician dashboard for remote patient monitoring and a notification system that alerts both patients and doctors when test results indicate potential deterioration. The company is also developing TLK-002, a second medical game targeting opioid dependency, marking expansion beyond ophthalmology.

Differentiator

Problem solved

Functional benefit

Brands

• OdySight®: Medical mobile application combining clinically validated vision tests with a puzzle game to monitor chronic maculopathies and engage patients in remote disease monitoring.

Products and services

• OdySight®

Quantifiable outcome

• 30,000+ patients and 1,200+ physicians adopted the platform as of 2025 with positive clinical results from 2-year national experimentation
• +2 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Three partnerships are on record, tiered major.

• Laboratoires ThéamajorStrategic or Co-development Partner · 28 June 2022Théa, a French laboratory specialized in eye treatments, partnered with Tilak Healthcare to promote OdySight® as the first remote monitoring solution in ophthalmology. Théa also participated as an investor in the €10M funding round.
• Novartis SpainmajorGTM or Marketing Partner · 22 September 2021Partnership with Novartis Spain to promote OdySight® to patients with chronic vision diseases, specifically for market deployment in Spain.
• Novartis FrancemajorGTM or Marketing Partner · 13 May 2019Exclusive co-promotion partnership with Novartis France to promote OdySight®, a digital solution for optimizing monitoring of patients with chronic eye diseases. Extended during COVID-19 crisis to ensure continuity of care.

Scale indicators10 records

Recent moves3 records

Expansion highlights6 records

Direct peers

• Notal Vision: Notal Vision develops ForeseeHome, a remote monitoring solution for age-related macular degeneration (AMD), directly competing with OdySight® in the home-based ophthalmology monitoring market. Both target chronic maculopathy patients with FDA-cleared/CE-marked digital tools.
• Sensimed: Sensimed develops the SENSIMED Triggerfish contact lens sensor for continuous 24-hour intraocular pressure monitoring in glaucoma patients. Similar concept of remote ophthalmology monitoring using connected health technology.

Broad incumbents

• Carl Zeiss Meditec: Carl Zeiss Meditec is a leading global ophthalmology medical technology company offering diagnostic devices, surgical equipment, and increasingly digital solutions. Represents a major incumbent that could develop or acquire competing remote monitoring capabilities.
• Heidelberg Engineering: Heidelberg Engineering specializes in diagnostic imaging solutions for ophthalmology including OCT and confocal microscopy used in retinal disease management. A broad incumbent in ophthalmic diagnostics that could expand into remote monitoring.

Emerging players

• Voluntis: Voluntis is a French digital therapeutics company developing connected software for chronic disease self-management (diabetes, oncology). Similar DTx platform approach and French origin makes it a comparable emerging player in digital therapeutics.
• Akili Interactive: Akili Interactive is a prescription digital therapeutics company developing video game-based treatments (initially for ADHD/cognition). Comparable DTx business model combining clinical validation with engaging game mechanics.
• Click Therapeutics: Click Therapeutics develops prescription digital therapeutics across multiple chronic conditions including depression, migraine, and oncology support. Similar DTx platform with pharmaceutical partnerships (Otsuka, Boehringer Ingelheim).
• Better Therapeutics: Better Therapeutics develops prescription digital therapeutics for chronic cardiometabolic conditions including type 2 diabetes. Similar DTx approach targeting chronic disease management with FDA pathway.
• WellDoc: WellDoc is a digital therapeutics company focused on chronic disease management, particularly diabetes, with FDA-cleared solutions. Pioneer in the DTx space with reimbursement track record.
• Big Health: Big Health develops digital therapeutics for mental health conditions including insomnia and anxiety. Comparable DTx business model combining clinical validation with engaging digital experiences.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/tilak-healthcare
• Xx.com/tilakhealthcare

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tilak Healthcare